Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
A Robarts' Scientist has generated a target-based primary in vitro cell-based screen for evaluating compounds or peptides affecting scar matrix deposition and remodeling during wound repair. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
iGen is a collagen implant, and is a biodegradable scaffold which can induce a regenerative non-scarring wound healing process without the use of medicine. The ophthalmology applications for iGen include glaucoma, pterygium, ocular tissue, and More
SmarBUCKL is produced with biocompatible and slow-resorbing biomaterials which will not induce immunoreactions and can be resorbed after implantation. The SmarBUCKL doesn't need to be exteriorized by a second operation after patient recovers. More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
Therapy for deafness More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Auditory
- Opthalmic
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us